Evidence map›Paper›PMID 35925074›Full record

ReviewInnere Medizin (Heidelberg, Germany)2022

[Post-COVID syndrome with fatigue and exercise intolerance: myalgic encephalomyelitis/chronic fatigue syndrome].

Herbert Renz-Polster, Carmen Scheibenbogen

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Innere Medizin (Heidelberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06118138 (Observational Study of Hyperbaric High Pressure Oxygen Therapy), which is not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06118138 completednot on this mapstarted 2023, after this paper: background citation

Observational Study of Hyperbaric High Pressure Oxygen Therapy (HBOT) in Patients With Post-COVID Syndrome (PCS) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

TypeobservationalSponsorCharite University, Berlin, GermanyRan2023 to 2025Enrolled60ConditionsPost-COVID ME/CFSArmsHyperbaric oxygen therapy (HBOT)
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Herbert Renz-Polster, Rohrmoos 10, 88267, Vogt, Deutschland. herbert.renz-polster@posteo.de.
Carmen ScheibenbogenCharité Fatigue Centrum der Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1 (Südstr. 2), 13353, Berlin, Deutschland. carmen.scheibenbogen@charite.de.
Charité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA sizable part of post-COVID syndrome meets the diagnostic criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). A doubling of cases of ME/CFS within the next years is therefore projected.

objectivesPresentation of the current state of knowledge on ME/CFS. MATERIALS AND

methodsUnsystematic review of the literature and of own contributions in research and patient care. RESULTS AND

conclusionsME/CFS is a neuroimmunological disease, mostly infection-induced, usually persisting throughout life. Clinically it is characterized by fatigue lasting at least 6 months and the defining core feature of exercise intolerance (post-exertional malaise, PEM). Exercise intolerance is defined as a worsening of symptoms after (even mild) everyday exertion, which usually begins after several hours or on the following day, is still noticeable at least 14 h after exertion, and often lasts for several days (up to weeks or longer). Furthermore, ME/CFS is characterized by pain, disturbances of sleep, thinking and memory, and dysregulation of the circulatory, endocrine, and immune systems. As a separate clinical entity, ME/CFS should be distinguished from chronic fatigue, which occurs as a symptom of a range of very different diseases. The diagnosis of ME/CFS is made clinically using established international diagnostic criteria and requires careful stepwise diagnosis to exclude other diagnoses. A causal therapy for ME/CFS has not been established; the focus is on symptoms relief, treatment of the often accompanying orthostatic intolerance, and assistance with anticipatory energy management (pacing).

Indexed as

COVID-19Fatigue Syndrome, ChronicHumansPainChronic fatigue syndromeLong COVIDPacingPost exertional malaiseSevere acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)

Identifiers

PMID35925074
PMCPMC9281337
OpenAlexW4285085253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.